What we do Aarti Drugs Ltd manufactures active pharmaceutical ingredients, intermediates, and specialty chemicals, serving global pharma markets with a focus on antibiotics and therapeutic APIs. |
Founded in 1,984 |
Market share Market leader in multiple APIs with global largest producer status in key molecules and diversified geographic presence across 100+ countries. |
Problem solved Provides essential raw materials and finished formulations to pharma companies, addressing critical drug manufacturing needs across various therapeutic segments. |
Top clients or who we serve Serves global pharmaceutical companies, government agencies in regulated and semi-regulated markets; B2B focus with exports to over 100 countries. |
Key management Prakash M. Patil (Chairman, MD & CEO), Adhish P. Patil (CFO & COO), Rashesh C. Gogri (Managing Director), Harshit M. Savla (Joint Managing Director) |
Our journey and innovations Incorporated in 1984, expanded into formulations in 2014, developed backward integration capabilities including methyl amines and salicylic acid plants, continuous capacity expansions and R&D innovations. |
Where we operate Operations and exports across India, Latin America, Europe, Asia, Africa, and established subsidiaries in Chile and India. |
Top products or what we offer Over 50 API molecules including antibiotics, anti-inflammatory, anti-diabetic APIs; formulations and specialty chemicals like benzene sulphonyl chloride. |
Top brands No specific consumer brands; flagship products include world-leading APIs like Nimesulide, Ketoconazole, Metronidazole Benzoate, Tinidazole, Fluoroquinolones, and Metformin. |
Raw materials needed Pharmaceutical raw materials including benzene derivatives and glyoxal for backward integrated synthesis of intermediates and APIs. |
Raw materials supplier Sourced internally via backward integration and external suppliers from chemical commodity markets. |
Recurring vs cyclical contribution Revenue is primarily recurring through long-term supply contracts and repeat orders from global pharmaceutical companies. |
Our industry position Among top API producers globally with diversified product portfolio and strong presence in regulated and emerging markets. |
Financial highlights Consolidated FY25 revenue Rs. 2387 Cr, PAT Rs. 168 Cr, steady export growth at ~35%, EBITDA margin ~12.7%, managing strong cash flows and balance sheet. |
Geographical revenue split Domestic contributes approximately 64%, exports 36%, spanning markets in Asia, Americas, Europe, Africa, and Latin America. |
Order book Not specified; steady order inflow supported by global demand and registration across 16 countries for formulations. |
Whats driving growth Capacity expansions, backward integration, geographic diversification, regulatory approvals, and growing global pharma demand. |
Our future plans Focus on scaling new greenfield projects, ramping up methyl amine and salicylic acid capacity, expanding formulation and specialty chemicals footprint. |
Our green promise Adoption of zero liquid discharge, carbon footprint reduction, eco-friendly packaging, and renewable energy initiatives. |
Our people and values Employs over 2,000 people emphasizing safety, ethical governance, diversity, and continuous employee development. |
Key challenges ahead Regulatory compliance, pricing pressures, raw material availability, and global market volatility. |
Interesting facts Largest global producer of several key APIs; operates diverse GMP-certified manufacturing across India with global regulatory approvals. |
Risks and strategy Mitigates risks through diversification, stringent quality control, R&D investment, compliance adherence, and phased capex to manage financial leverage. |
